Cite
HARVARD Citation
Cho, B. et al. (n.d.). 1275PSafety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC). Annals of oncology. p. . [Online].